sun pharma (CreditSuisse) New report: US business turning around

Strong growth in India continues and US business is back on track; Cranbury facility clearance, accretive use of US$800 mn cash provide upside; High returns and strong B/S warrants higher multiple to peers
Date Rating Target Price Recommendation Price Broker house
25 May 2011 outperform (from neutral) 515 (From 425) 426 CreditSuisse Report

No comments:

Post a Comment